Index

A1C values, 63
absolute neutrophil count (ANC), 6, 7, 115
baseline, 63
DARC genotype, 119
low baseline, addressing, 120–122
low, and treatment interruption, 131–134
monitoring guidelines, USA, 126
threshold, 116, 117
UK hematologic monitoring, 128
ACHIEVE protocol, 217
adherence. See nonadherence
adolescents, 277, 279–285
adverse effects of clozapine, 284
intellectually disabled, 290
plasma clozapine levels, 282
principles for clozapine use, 281
randomized double-blind studies, 279
African descent, 6, 117, 118, 119, 280
aggression, 27–31, 289
akathisia, 280, 281, 284
alanine aminotransferase (ALT), 259, 260, 269, 270, 271
alpha, antagonism, 99, 166, 247
alpha-synuclein, 33
amisulpride, 49, 184
amphetamine, 163
anemia, 259, 267–268
general approach to, 265
incidence of, 259
anticholinergics, 73
approximate equivalents, 82
cholinergic rebound, 80, 81
constipation and, 144, 145
daily maximum limits, 82
equivalencies, 74, 145
sialorrhea and, 173, 178
anticonvulsants, 193, 195, 198, 200
antidepressants, tricyclic, 74, 144
antihypertensives, 75
antiparkinsonian medications, 145
antipsychotics. See also individual antipsychotics
augmenting clozapine, 48–49
consensus criteria for an adequate trial, 15
double-blind trials, 12
mortality studies, 20
plasma levels, 45
provision of appropriate, 83–86
real-world effectiveness studies, 17
tapering, 75
weight gain and, 210, 211
antisocial personality disorders, 29
aripiprazole, 49, 212
OCD and, 253
sedation and, 162
armodafinil, 163
aromatic hydrocarbon receptor (AhR), 96
aspartate aminotransferase (AST), 259, 260, 269, 270, 271
aspiration pneumonia, 173
INDEX

atenolol, 168
atonic seizures, 194
atropine, 173, 178, 179, 181
Australia, clozapine registration, 66
bacterial infections, 103, 105, 106–108
clozapine management during, 107
minimization of risk, 135
bariatric surgery, 212
baseline laboratory measures, 63
baseline vital signs, 62
baseline work-up, 62, 65
baseline, low, ANC, 120–122
Bazett formula, 48, 64, 65, 167
benign ethnic neutropenia (BEN), 6, 7, 66, 115, 118–119
ANC threshold, 117
definition of, 119
diagnosis, 119
hematologic monitoring, 116
hematologic monitoring, UK, 129
hematologic monitoring, USA, 127
benzodiazepines, 73
benztrypine, 153
cholinergic rebound, 81, 82
BID dosing, 97
binding profile, 98–102
bioavailability, 72, 91, 93
bipolar disorder, manic phase of, 32
bisacodyl, 146
body mass index (BMI), 63, 65, 208
botulinum toxin-A, 181, 182
botulinum toxin-B, 173, 178, 180–183
breastfeeding, 277, 278, 295–296
Brief Psychiatric Rating Scale (BPRS), 48, 49, 51
Bristol Stool Form Scale, 143, 144, 145
bulk-forming laxatives, 147, 148
bupropion, 218
caffeine, 96
Cal-DSH, 149, 150
Canada, clozapine registration, 66
carbachol, 99, 176
carbamazepine, 69, 199, 200
cardiac malformations, 294
cardiomyopathy, 167, 224, 225, 236–238
cardiovascular disease, 204, 205, 216
caregivers
checklist of information, 70
dosages and, 104
initiating clozapine and, 61
monitoring role, 72
CATIE study, 160, 164
CBC monitoring, point-of-care, 136
Child–Pugh criteria, 93
children, 277, 279–285
adverse effects of clozapine, 284
plasma clozapine levels, 282
principles for clozapine use, 281
randomized, double-blind studies, 279
clophramazine, 10, 81, 190
cholinergic rebound, 78, 82
ileus risk, 74
Kane study, 12
liver function and, 269
cholestasis, 269
cholinergic rebound
clophramazine, 78, 82
clozapine, 80
definition, 79
diabetes patients, 214
ileus and, 153
management of, 81–83
neuroleptic malignant syndrome, 250
severe neutropenia, 134
symptoms, 80
ciprofloxacin, 69
Clinical Global Impression (CGI) severity scale, 51, 55, 285
clonazepam, 199
clonidine, 177, 183
clozapine
INDEX

adverse effects, 105, 106, 284, 287, 288, 292. See also individual adverse effects
binding profile, 98–102
cholinergic rebound, 80
comparative double-blind trials, 12
discontinuing. See discontinuing clozapine
dose reduction. See dose reduction
ECT and, 200
FDA approval, 117
FDA prescribing guidelines, viii
first synthesis of, 10
hematologic monitoring. See hematologic monitoring
impact of delays in commencing, 16
initiating. See initiating clozapine mania and, 284
metabolic adverse effects. See metabolic adverse effects
metabolism and kinetics, 91–98
mortality and, 18, 21, 204
pivotal trial, 12
plasma levels. See plasma clozapine levels
pregnancy outcome and, 294–295
prescriber fear, 6
primary metabolites, 91
product registration, 11
real-world effectiveness studies, 16, 17
slow tapering of, 81
smoking and, 97
suicide and, 26
titrating. See titration
underutilization, viii, 1
underutilization, adolescents, 282
underutilization, treatment-resistant schizophrenia, 4, 6
utilization, strategies for increasing, 7
clozapine efficacy, 11, 37

background, 10–13
Parkinson’s disease psychosis, 33–36
plasma levels monitoring, 108–109
psychogenic polydipsia, 21–24
suicidality, 25
treatment-intolerant schizophrenia, 24
treatment-resistant mania, 31–33
treatment-resistant schizophrenia, 13–21
violence and aggression, 27–31
clozapine positive symptom nonresponse, 45–56
antipsychotic augmentation, 48–49
ECT and, 50–53
increasing plasma levels, 47–48
nonantipsychotic augmentation, 53–55
patient adherence and, 45–46
clozapine resource centers, 8
clozapine-N-oxide, 91, 98
CLOZARIL, 125, 134, 262
Clozaril Collaborative Study Group, viii
colonic transit time (CTT), 140, 142, 148
complete blood count (CBC), 63, 71
compression stockings, 166
congenital malformations, 277, 293, 295
congestive heart failure, 166
constipating medications, 75
constipation, 19, 74, 140, 141–148, 149–155
criteria, 143–144
first-line agents for, 146, 148
opioid-induced, 143, 144
prevalence and postulated mechanisms, 142
PRN medications, 152
treatment, 144–153
corpora cavernosa, 247
INDEX

C-reactive protein (CRP), 65, 225, 230, 231, 233
creatinine, 233
CYP
inducers, 94
inhibitors, 93, 94
CYP 1A2, 67, 69, 85
clozapine metabolism and, 92
inducers, 95
infections and, 107
inhibitors, 95
metabolic ratio and, 102, 103
smoking, caffeine and genetic polymorphisms, 94–97
CYP 2D6, 85, 95
inhibitors, 95
CYP 3A4, 95
CYP/P-glycoprotein (PGP) inducer effects, 93
CYP polymorphisms, 94, 96
daily maximum limits, 82
DARC genotype, 118, 119, 120
delays in commencing clozapine, 16
delusions, violence and, 28
deutetrabenazine, 252
diabetes mellitus, 204, 207, 213–215
criteria for, 208
diagnosis, 208
gestational, 295, 296
initiating clozapine, 63
risk factors, 214
diabetic ketoacidosis (DKA), 207, 213
dietary counseling, 205, 206, 217
diminishing tolerability, 47, 109
diphenhydramine, 81, 82
disability-adjusted life year, 1
See also cholinergeric rebound metabolic effects and, 207
myocarditis, 231
orthostasis and, 158
Parkinson's disease psychosis, 86–87
priapism, 247
sedation and, 158, 160
sialorrhea and, 173
divalproex, 53, 54, 55, 94, 125.
See also valproate
adverse effects, 259, 260
seizures and, 193, 195, 198, 200
thrombocytopenia and, 266
divided doses, plasma levels and, 104
dizziness, 165
docusate, 141, 146, 147
donepezil, 80
dopamine D₂ antagonism, 99, 250
occupancy with clozapine, 101
dopamine D₃ antagonism
intolerance, 12, 13, 24, 83
antipsychotic options, 84
antipsychotic trials, 16
dose reduction, 107
constipation and, 152
sedation and, 161
dose titration trial, 109, 110
DRESS, 225, 228, 234, 262
mortality, 234
Drooling Severity and Frequency Scale, 172, 177, 178, 179
drug abuse
methylphenidate and
amphetamine, 163
modafinil and, 163
DSM-5, psychosis scoring, 55
Duffy antigens, 118
Dutch Clozapine Collaboration Group, 8
dyslipidemia, 63, 205, 207, 215
ECG, 64, 65, 105, 167
cardiomyopathy, 237
myocarditis, 230, 231, 233
necessity of, 65
ECT
clozapine and, 200
clozapine nonresponders, 50–53
EEG, 194
seizures and, 193
elimination half-life, 298
INDEX

enemas, 152
enuresis, 242, 243, 244–247, 254
approaches to treatment, 246
eosinophilia, 116, 131, 259, 261–264
DRESS, 225, 228, 234, 262
incidence of, 258
thresholds, 262
US language on, 262
eosinophils, 261
baseline, 63
reference ranges, 131
UK reference ranges, 261
ephedrine, 246
epilepsy, 195
erectile dysfunction, 247
ethnicity. See also African descent
diabetes risk factor, 214
metabolic adverse effects and, 209
exercise, 205, 206, 216–217
extrapyramidal symptoms, 251
factor Xa inhibitors, 249
falls, 158, 287
famotidine, 54
fatty liver index, 269
FDA
clozapine approval, 117
clozapine prescribing guidelines, viii
inhibitor/inducer definitions, 94
fever, 62, 224, 225, 226–227
clozapine-related, case series, 227
definition, 226
general principles of approaching, 228
filgrastim, 133, 134–136, 267
first-dose effect, 166
floppy infant syndrome, 295
fludrocortisone, 165, 166
fluvoxamine, 69
formulations, 72, 91, 93
Framingham Formula, 64, 65
Fridericia Formula, 64, 65
gabapentin, 198
G-CSF levels, 261, 264
generalized seizures, 194
 genetic polymorphisms, 94, 96
gestational diabetes mellitus, 295, 296
glucagon-like peptide-1 (GLP-1), 211
 glutamate neurotransmission, 100
 glycine, 53
glycopyrrolate, 185
sialorrhea, 173, 178
goserelin, 248
granulocytosis, 132
guanfacine, 183
Hale classification, 295
hallucinations, 28, 86
haloperidol, 49
aggression and, 31
Kane study, 12
response threshold, 85
heart transplantation, 238
hematologic guidelines, USA and UK, 117
hematologic monitoring. See also absolute neutrophil count (ANC)
UK, 116, 128
USA, 116, 126, 127
HemoCue WBC DIFF, 136
hemoglobin, 267
hepatic function abnormalities, 260, 268–271
general approach to tests, 270
HF-1854, 10
high-density lipoprotein (HDL), 215
histamine H1 antagonism, 99
HLA markers, 124, 125
hyperosmolar hyperglycemic states (HHS), 207
hypersalivation. See sialorrhea
hypertension, 207, 214
criteria for, 208
hypertriglyceridemia, 215
## Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hyponatremia</td>
<td>21</td>
</tr>
<tr>
<td>hypotension</td>
<td>69</td>
</tr>
<tr>
<td>orthostatic. See orthostasis</td>
<td></td>
</tr>
<tr>
<td>ileus</td>
<td></td>
</tr>
<tr>
<td>mortality, 140, 142, 153</td>
<td></td>
</tr>
<tr>
<td>rechallenging, 154</td>
<td></td>
</tr>
<tr>
<td>risk, 73, 142</td>
<td></td>
</tr>
<tr>
<td>treatment, post-rechallenging, 155</td>
<td></td>
</tr>
<tr>
<td>when to suspect, 154</td>
<td></td>
</tr>
<tr>
<td>iloperidone, 84</td>
<td></td>
</tr>
<tr>
<td>impulsive violence, 28, 29</td>
<td></td>
</tr>
<tr>
<td>incontinence, 242, 243, 244–247, 254</td>
<td></td>
</tr>
<tr>
<td>approaches to treatment, 246</td>
<td></td>
</tr>
<tr>
<td>inducers, 93</td>
<td></td>
</tr>
<tr>
<td>CYP, 94, 95</td>
<td></td>
</tr>
<tr>
<td>strength of, 94, 95</td>
<td></td>
</tr>
<tr>
<td>inflammatory cytokines, 107</td>
<td></td>
</tr>
<tr>
<td>informed consent, 70</td>
<td></td>
</tr>
<tr>
<td>inhibitors, 93</td>
<td></td>
</tr>
<tr>
<td>CYP, 94, 95</td>
<td></td>
</tr>
<tr>
<td>strength of, 94, 95</td>
<td></td>
</tr>
<tr>
<td>initiating clozapine, 61–62, 65–75</td>
<td></td>
</tr>
<tr>
<td>baseline laboratory measures, 63</td>
<td></td>
</tr>
<tr>
<td>baseline vital signs, 62</td>
<td></td>
</tr>
<tr>
<td>baseline work-up, 62, 65</td>
<td></td>
</tr>
<tr>
<td>checklist of information, 70</td>
<td></td>
</tr>
<tr>
<td>formulations, 72</td>
<td></td>
</tr>
<tr>
<td>managing orthostasis, 166</td>
<td></td>
</tr>
<tr>
<td>managing sedation, 161</td>
<td></td>
</tr>
<tr>
<td>monitoring during, 72</td>
<td></td>
</tr>
<tr>
<td>monitoring, inpatient, 72</td>
<td></td>
</tr>
<tr>
<td>monitoring, outpatient, 72</td>
<td></td>
</tr>
<tr>
<td>patient discussions prior to, 70</td>
<td></td>
</tr>
<tr>
<td>QT correction formula, 65</td>
<td></td>
</tr>
<tr>
<td>registration, 66</td>
<td></td>
</tr>
<tr>
<td>tapering concomitant medications, 73–75</td>
<td></td>
</tr>
<tr>
<td>titration, 67–70</td>
<td></td>
</tr>
<tr>
<td>instrumental violence, 28</td>
<td></td>
</tr>
<tr>
<td>insulin resistance, 205, 206, 213</td>
<td></td>
</tr>
<tr>
<td>intellectual disability (ID) patients,</td>
<td></td>
</tr>
<tr>
<td>adverse effects, 292</td>
<td></td>
</tr>
<tr>
<td>nonpsychotic, 290–291</td>
<td></td>
</tr>
<tr>
<td>psychotic, 291</td>
<td></td>
</tr>
<tr>
<td>interleukin-5 (IL-5), 261</td>
<td></td>
</tr>
<tr>
<td>InterSePT study, 25, 26</td>
<td></td>
</tr>
<tr>
<td>interstitial nephritis, 225, 228, 232</td>
<td></td>
</tr>
<tr>
<td>routine laboratory monitoring, 233</td>
<td></td>
</tr>
<tr>
<td>summary of cases, 232</td>
<td></td>
</tr>
<tr>
<td>intramuscular (IM) formulation, 72, 91</td>
<td></td>
</tr>
<tr>
<td>ipratropium, 173, 178, 179, 181</td>
<td></td>
</tr>
<tr>
<td>irritable bowel syndrome (IBS), 149</td>
<td></td>
</tr>
<tr>
<td>Kane criteria, 13</td>
<td></td>
</tr>
<tr>
<td>Kane study, 12</td>
<td></td>
</tr>
<tr>
<td>KiniM receptors, 98</td>
<td></td>
</tr>
<tr>
<td>laboratory error, 105, 297</td>
<td></td>
</tr>
<tr>
<td>lactulose, 146</td>
<td></td>
</tr>
<tr>
<td>lamotrigine, 198, 200</td>
<td></td>
</tr>
<tr>
<td>left ventricular dysfunction, 231</td>
<td></td>
</tr>
<tr>
<td>left ventricular ejection fraction (LVEF), 225, 236, 237</td>
<td></td>
</tr>
<tr>
<td>leukocytosis, 264</td>
<td></td>
</tr>
<tr>
<td>general approach to, 265</td>
<td></td>
</tr>
<tr>
<td>incidence of, 258</td>
<td></td>
</tr>
<tr>
<td>leukopenia, 117</td>
<td></td>
</tr>
<tr>
<td>levetriacetam, 199, 200</td>
<td></td>
</tr>
<tr>
<td>levodopa psychosis, 34</td>
<td></td>
</tr>
<tr>
<td>levodopa-induced dyskinesias (LID), 35</td>
<td></td>
</tr>
<tr>
<td>Lewy bodies, 33</td>
<td></td>
</tr>
<tr>
<td>lifestyle modification, 216–217</td>
<td></td>
</tr>
<tr>
<td>linaclootide, 150, 151</td>
<td></td>
</tr>
<tr>
<td>lithium, 125, 264</td>
<td></td>
</tr>
<tr>
<td>augmentation, 132</td>
<td></td>
</tr>
<tr>
<td>granulocytosis and, 132</td>
<td></td>
</tr>
<tr>
<td>lubiprostone, 149, 150, 151</td>
<td></td>
</tr>
<tr>
<td>magnesium, 147, 148</td>
<td></td>
</tr>
<tr>
<td>magnesium citrate, 152</td>
<td></td>
</tr>
<tr>
<td>magnesium hydroxide, 152</td>
<td></td>
</tr>
</tbody>
</table>
INDEX

313

mania, 80, 253, 284
treatment-resistant, 31–33
clozapine nonadherence. See nonadherence
memantine, 54
metabolic adverse effects, 205–219.
See also weight gain
discontinuing clozapine, 207
monitoring parameters, 208
principles of managing on clozapine, 206
metabolic ratio (MR), 92, 102, 281
adolescents and children, 283
guidelines for interpreting, 103
infections and, 106–108
older patients, 286
overdose and, 298
metabolic syndrome, 65, 204, 207
components of, 207
criteria for, 208
prevalence of, 213
metabolism, clozapine, 91–98
metformin, 205, 206, 207,
211–212
children and adolescents, 281
methylphenidate, 163
mineral oil (liquid paraffin), 148
minocycline, 54
mirabegron, 245, 246
mirtazapine, 100
modafinil, 163
monitoring, 71
inpatient, 71
outpatient, 71
mortality
clozapine and, 18–21, 204
DRESS, 234
ileus, 140, 142, 153
postmortem redistribution, 278,
299–301
severe neutropenia, 114, 134
smoking, 218
suicide and, 25
muscarinic M1/M3 antagonism, 99
muscarinic M1/M5 agonism, 99
muscarinic M3 antagonism, 245
muscarinic antagonism, 142, 175,
176
muscarinic intrinsic activity, 99, 176
myocarditis, 65, 168, 195, 225,
228–232
essential facts, 231
incidence of, 229
monitoring for, 71
routine laboratory monitoring, 233
time to onset, 229
myoclonic jerking, 297
neuroleptic malignant syndrome
(NMS), 24, 243, 244, 250–251
diagnostic criteria, 251
neutropenia, 11, 195, 200
ANC levels, monitoring, 126
BEN. See benign ethnic
neutropenia (BEN)
children and adolescents, 280
hypothesized mechanism, 125
other sources of, 120
severe. See severe neutropenia
terminology, 116
time course and risk factors, 117
valproate and, 122, 125
neutrophilia, 258, 264
causes of, 264
nicotine replacement therapy, 219
NMDA glutamate receptors, 53, 54,
100
Nocturnal Hypersalivation Rating
Scale, 172, 178, 179
nonadherence, 45–46, 60
plasma levels and, 104
rates, 16
nonalcoholic fatty liver disease
(NAFLD), 215, 269, 270
nonantipsychotic augmentation
clozapine nonresponders, 53–55
norclozapine, 68, 91. See also
metabolic ratio (MR)
binding profile, 98–102
infections and, 106
plasma levels, 102
sialorrhea and, 175
INDEX

obesity, criteria for, 208
obsessive compulsive disorder, 243, 244, 252
approach to new onset, 253
olanzapine, 84
aggression and, 31
cholinergic rebound, 81
double-blind trials, 13
Parkinson's disease psychosis, 35, 36
response threshold, 85
suicide and, 26
tapering, 74
older patients, 277, 285–289
adverse effects of clozapine, 287, 288
omeprazole, 69, 72, 92, 93, 95, 102, 121, 161, 165
opioids, constipation and, 143, 144
oral formulations, 72, 91
oral suspension, 72
orally disintegrating tablet (ODT), 72
organized violence, 28
orthostasis, 62, 145, 164–166, 169
clozapine initiation, 75
definition, 164
falls and, 158
seizures and, 194
tachycardia and, 168
vital signs, 72
overactive bladder, 246
overdose, 277, 278, 297–299
paralytic ileus, 140
Parkinson's disease (PD), 33
medications, 145
Parkinson's disease psychosis (PDP), 33–36
consensus definition, 33
discontinuing clozapine, 86–87
titrination levels, 70
partial seizures, 194
patient discussions, 70
checklist, 70
patient nonadherence. See nonadherence
PEG-3350, 141, 146, 148
perphenazine, 20
Petrides' study, 51
PGP, 92
CYP/PGP inducer effects, 93
phenytoin, 69, 122, 199, 200
physical activity vital sign (PAVS), 210, 216
pimavanserin, 70, 83
5HT₂A affinity, 100
D₄ antagonism intolerance, 84
Parkinson's disease psychosis, 36, 86
pirenzipine, 176
pivotal clozapine trial, 12
plasma antipsychotic levels, 45
plasma clozapine levels, 46, 91, 102–109
adolescents and children, 282
conversion formulas, 108
decreasing, for constipation, 152
early in treatment, 69
infections and, 106–108
markedly below expected, 104
markedly higher than expected, 106–108
monitoring efficacy, 108–109
nonresponders, 47
older patients, 286, 288
overdose and, 297
postmortem redistribution, 300
principles for obtaining, 104
threshold, 47
units used, 90, 108
upper limits, 109, 110
platelet count, 116, 131, 265–267
platelets, UK reference ranges, 131, 261
plecanatide, 150, 151
point of futility, 47, 109
point-of-care CBC monitoring, 136
Porirua constipation protocol, 148
Positive and Negative Syndrome Scale (PANSS), 48
INDEX

postmortem redistribution, 278, 299–301
predatory violence, 28
pregnancy, 277, 278, 293–295
anticonvulsants and, 200
clozapine and, 294–295
thrombocytopenia and, 266
prescriber fear, 6
priapism, 243, 247–248, 254
primary metabolites, clozapine, 91
primary polydipsia, 21, 23
propensity scores, 293
propranolol, 168, 281
prucalopride, 141, 151, 154
psychogenic polydipsia, 21–24
psychotic violence, 28
psychotropics
constipation and, 145
tapering, 74
PSYCLOPS trial, 34
psyllium, 148
PubMed, clozapine publications in, 1
pulmonary embolism, 248, 250
QHS dosing, 97
QT correction formula, 65
QT monitoring, 65
QT prolongation, 167
quetiapine, 17
adverse effects, 24
D₂ antagonism intolerance, 84
mortality rates, 20
Parkinson’s disease psychosis,
35, 36, 87
tapering, 74
rechallenging
eosinophilia, 262
ileus, 154
interstitial nephritis, 233
myocarditis, 231
priapism, 247
severe neutropenia, 134
RegiSCAR, 234
registration, 66
repetitive transcranial magnetic stimulation (rTMS), 53
response threshold, 46, 47, 69, 109
haloperidol, 85
olanzapine, 85
rhabdomyolysis, 297
ribavirin, 135
risperidone, 83, 100, 294
Rome IV diagnostic criteria, 143
salivary glands, 174
schizoaffective disorder, bipolar type, 32
schizophrenia
antipsychotic mortality studies, 20
costs in the US, 2
disease burden of, 1
enuresis and, 244
prevalence, 1, 3
prevalence, age-standardized, 3
real-world effectiveness studies, 17
treatment-intolerant, 24
treatment-resistant. See treatment-resistant schizophrenia
violence risk estimates, 27
schizophrenia spectrum disorders
antipsychotic options, 84, 85
clozapine initiation, 60
mortality and, 25
plasma levels, 69
suicidality and, 25
secondary polydipsia, 21
secretagogues, 141, 149–151, 154
sedation, 159, 160–164, 169
effects, 73
falls and, 158
seizures, 48, 191–200, 201
clozapine and, 192, 193, 194
dose-dependency and, 191, 193,
196–197
neonatal, 295
treatment of, 197–200
types and frequencies, 194
INDEX

sennosides, 146
serositis, 225, 228, 235
serotonergic motility agents, 149–151
serotonin 5HT2a inverse agonism, 99
serotonin 5HT2a occupancy with clozapine, 101
serotonin 5HT2a receptors, 34, 86
sertraline, 253
serum creatinine, 233
serum osmolality, 21, 22
severe cutaneous adverse reactions (SCARs), 234
severe neutropenia, 115, 116
breastfeeding and, 296
estimates for clozapine, 117
fever and, 228
mortality from, 114, 134
other medications and, 121
rechallenging, 134
time course of, 123–125
sialorrhea, 19, 173–186
clozapine-induced, 175–177
prevalence, 172
rechallenging, 134
treatment principles, 177–185
single nucleotide polymorphisms (SNPs), 96
smoking, 218–219
anticholinergics and, 74, 82
clozapine and, 97
CYP 1A2 activity and, 96
inhibitor/inducer effects and, 94
monitoring, 210
mortality rates, 218
titration and, 67, 68, 69
SNARE proteins, 180, 182
sodium benzoate, 54
SSRIs, 252, 253
Stevens–Johnson Syndrome, 200, 234
stimulants, 141
stool form nomenclature, 143–144, 145
STRIDE protocol, 217
stuttering, 191, 197
substance use, violence and, 27
suicidality, 25, 278
InterSePT study, 25, 26
overdose and, 298
type 1 and type 2 events, 26
sulpiride, 184
systemic inflammation, 216
tachycardia, 62, 65, 159, 166–167, 169, 298
decision algorithm, 167
definition, 166
thrombin inhibitors, 249
thrombocytopenia, 122, 131, 259, 265–267
general approach to, 265
incidence of, 258, 266
thrombocytosis, 259, 265–267
general approach to, 265
incidence of, 258
timing, plasma levels and, 104
titration, 67–70
children and adolescents, 277, 281, 284
clozapine, 47
dose titration trial, 109, 110
older patients, 285, 287
principles of, 67, 110
rapid, 68, 69
slower, 68
tonic–clonic seizures, 194
topiramate, 53, 54, 55
transabdominal ultrasound, 245, 246
traveling, difficulties in, 61
treatment-intolerant schizophrenia, 24
treatment-resistant mania, 31–33
treatment-resistant schizophrenia adolescents, 279, 280, 282
children, 279
clozapine efficacy, 13–21
INDEX

clozapine underutilization, 4, 6
consensus criteria for an adequate trial, 15
costs of, 2
ECT and, 200
Kane criteria, 13
olanzapine trials, 13
pivotal clozapine trial, 12
plasma level ranges, 109
prevalence, 2
suicidality and, 25
tricyclic antidepressants, 74, 144
trihexyphenidyl, 82
troponin, 65
troponin I/T level, 225, 230, 231, 233
UGT1A 4, 94
UK
clozapine prescriptions, 6
clozapine registration, 66
eosinophil/platelet reference ranges, 131, 261
hematologic monitoring, 116, 128
UK Diabetes Prevention Program trial, 213
urinalysis, 233
urine osmolality, 21, 23
urodynamic testing, 246, 247
USA. See also FDA
clozapine prescribing guidelines, 94
clozapine prescriptions, 5
clozapine registration, 66
costs of schizophrenia, 2
eosinophilia, language on, 262
guidelines on dose adjustment, 95
hematologic guidelines, 117
hematologic monitoring, 116, 126, 127
valbenazine, 252
valproate, 54, 198, 200. See also divalproex
neutropenia risk, 122, 125
valproic acid, 94, 195
varenicline, 218
venous thromboembolism, 243, 248–250, 254
risk assessment tool, 249
violence, 27–31, 163
risk estimates in schizophrenia, 27
viral infections, 103, 105, 106–108
clozapine management during, 107
minimization of risk, 135
visual hallucinations, 86
VMAT2 inhibitors, 24, 252
waist circumference, 65, 208, 209
warfarin, 249
weight gain, 63, 65, 205
antipsychotic-related, 210, 211
children and adolescents, 281
nonmodifiable risk factors, 206
white blood cells (WBCs), 7, 116
leukocytosis, 264
low, and treatment interruption, 131–134
racial variations, 118
UK hematologic monitoring, 128
WHO Global Burden of Disease Study 2016, 1
withdrawal symptoms. See cholinergic rebound
Young Mania Rating Scale (YMRS) score, 32, 80
Young Mania Rating Scale (YMRS) score, 33, 79
Zollinger–Ellison syndrome, 54